Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from April 2022.
FDA
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy -
Read more: Psychedelic Policy on the Federal Level: Key Takeaways from a Petrie-Flom Center Panel Psychedelic Policy on the Federal Level: Key Takeaways from a Petrie-Flom Center Panel
Key takeaways from a virtual panel discussion with three leading psychedelic policy advocates.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from March 2022.
-
Read more: Exercise Equipment Advertisements and Consumer Distrust Exercise Equipment Advertisements and Consumer Distrust
Massive and misleading promises are an unfortunate reality for many fitness products. But regulators can promote accountability.
-
Read more: Pig Hearts for Humans and the FDA Pig Hearts for Humans and the FDA
Researchers and clinicians alike see the potential for genetically modified animal organs to serve as a solution to our organ transplant and supply issues.
-
Read more: Microdosing at Work: Business and Legal Implications Microdosing at Work: Business and Legal Implications
Private sector employers should reconsider the implications of a blanket prohibition on workplace use of controlled substances.
-
Read more: Introducing Affiliated Researchers for the Project on Psychedelics Law and Regulation Introducing Affiliated Researchers for the Project on Psychedelics Law and Regulation
We are excited to welcome our inaugural group of affiliated researchers for the Project on Psychedelics Law and Regulation (POPLAR).
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from February 2022.
-
Read more: Tobacco Issues Awaiting Robert Califf at the FDA Tobacco Issues Awaiting Robert Califf at the FDA
Yesterday, the Senate confirmed Dr. Robert Califf for his second, non-consecutive term as Commissioner of the U.S. Food and Drug Administration.
-
Read more: Reflections on Procedural Barriers to Pediatric COVID Vaccine Access Reflections on Procedural Barriers to Pediatric COVID Vaccine Access
Bureaucratic tape is causing delays in distributing these critical vaccines to our youngest children.
